JPRN-UMIN000005284已完成2 期
Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage4 - Phase2 study of CBDCA / PTX + Bevacizumab to non-small-cell lung cancer with pleural efussion
Osaka Prefectural Medical Center for Respiratory and Allergic diseases0 个研究点目标入组 20 人开始时间: 2011年3月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of pleurodesis 2)Severe infection except for non-active hepatitis C 3)Fever more than 38 degree 4)Severe comorbidity (heart failure/kidney failure/hepatic failure/uncontrollable diabetes/uncontrollable hypertension, etc) 5)Active double cancer 6)Symptomatic brain metastasis 7)History of hemoptysis with 2.5mL or more 8)Pericardial effusion requiring drainage 9)Interstitial pneumonia or pulmonary fibrosis detectable on X ray 10)History of drug sensitivity 11)Pregnant or lactating women 12)Psychiatric disease or mental trouble 13)Continuing administration of steroid 14)Evaluated to be ineligible by a physician for other reasons
研究者
相似试验
已完成
2 期
Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussionon-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion in stage4JPRN-UMIN000013329Osaka Prefectural Medical Center for Respiratory and Allergic diseases20
进行中（未招募）
不适用
A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. - bevacizumab plus erlotinib beyond progressioEUCTR2007-005523-15-NLRadboud University Medical Centre
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
已完成
2 期
Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.JPRN-UMIN000006767Shizuoka Cancer Center32
招募中
2 期
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45